RankAlpha logo
Back to Rankings

TARA

Protara TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Primary-source updates show genuine momentum: the lead NMIBC program posted a 68.0% six-month CR rate in the first 25 BCG-unresponsive patients, management reiterated 2H 2026 registrational milestones, and the LM program has Breakthrough/Fast Track support plus an expected 1H 2026 regulatory update [#8-K-2026-03-30][#PR-2026-03-10][#PR-2026-01-05].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +13.2.
What can break
Clinical and regulatory outcomes remain binary across both TARA-002 and IV Choline Chloride.
Momentum
17
Value
41
Sentiment
72
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $9.00 · Bear $2.75
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $25.71
Why
Momentum17 · Δ7d -11.7
Value41 · Δ7d +0.1
Sentiment72 · Δ7d +13.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
17
34% active weight
Current posture
7d trendSoftening
Δ7d
-11.7
Δ21d
-16.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
72
33% active weight
Current posture
7d trendImproving
Δ7d
+13.2
Δ21d
+25.3
Why this grade

Composite grade D. Momentum 16.5 / Value 41.1 / Sentiment 71.9

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$243.93M
Beta
1.37
Shares Out
51.63M
P/E (TTM) · Derived
-2.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.69
Rev YoY
-
EPS YoY
+37.6%
Gross Margin
-
Op Margin
-
Net Debt
-$170.29M
Current Ratio
13.69
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology